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BACKGROUND: Altered DNA repair may be associated with aggressive tumour biology and impact upon response to chemotherapy
and radiotherapy. We investigated whether expression of human AP endonuclease (APE1), a key multifunctional protein involved in
DNA BER, would impact on clinicopathological outcomes in ovarian, gastro-oesophageal, and pancreatico-biliary cancer.
METHODS: Formalin-fixed human ovarian, gastro-oesophageal, and pancreatico-biliary cancers were constructed into TMAs.
Expression of APE1 was analysed by IHC and correlated to clinicopathological variables.
RESULTS: In ovarian cancer, nuclear APE1 expression was seen in 71.9% (97 out of 135) of tumours and correlated with tumour type
(P¼0.006), optimal debulking (P¼0.009), and overall survival (P¼0.05). In gastro-oesophageal cancers previously exposed to
neoadjuvant chemotherapy, 34.8% (16 out of 46) of tumours were positive in the nucleus and this correlated with shorter overall
survival (P¼0.005), whereas cytoplasmic localisation correlated with tumour dedifferentiation (P¼0.034). In pancreatico-biliary
cancer, nuclear staining was seen in 44% (32 out of 72) of tumours. Absence of cytoplasmic staining was associated with perineural
invasion (P¼0.007), vascular invasion (P¼0.05), and poorly differentiated tumours (P¼0.068). A trend was noticed with advanced
stage (P¼0.077).
CONCLUSIONS: Positive clinicopathological correlations of APE1 expression suggest that APE1 is a potential drug target in ovarian,
gastro-oesophageal, and pancreatico-biliary cancers.
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DNA base excision repair (BER) is involved in the repair of bases
that have been damaged by alkylation, oxidation, or ring-
saturation in addition to processing deaminated bases and DNA
single-strand breaks. Although there is more than one sub-
pathway of BER, in most cases excision of a damaged base by a
DNA glycosylase enzyme leads to the formation of a potentially
cytotoxic apurinic/apyrimidinic (AP) site intermediate (Hickson
et al, 2000). This is a target for an AP endonuclease (APE1), which
cleaves the phosphodiester backbone on the 50 side of the AP site
via a hydrolytic mechanism. The major AP endonuclease in human
cells, APE1 (also called previously HAP1, Ref-1, and APEX1),
accounts for over 95% of the total AP endonuclease activity in
most cultured human cell lines (Demple et al, 1991; Robson and
Hickson, 1991). In addition to its DNA-repair activity, APE1 also
regulates redox function (Robson and Hickson, 1991) and
transcription (Bhakat et al, 2003; Fuchs et al, 2003).
Using either antisense oligonucleotides or siRNA approaches,
several groups have reported that depletion of intracellular APE1
sensitises mammalian cells to a variety of DNA-damaging agents
(Chen and Olkowski, 1994; Ono et al, 1994; Walker et al, 1994;
Robertson et al, 1997; Evans et al, 2000; Silber et al, 2002).
In pancreatic cancer cell lines for example, downregulation of
APE1 potentiated the cytotoxicity of gemcitabine (Lau et al, 2004).
APE1 downregulation has also been shown to block ovarian
cancer cell growth (Fishel et al, 2008). In melanoma cell lines,
APE1 downregulation led to increased apoptosis, whereas APE1
overexpression conferred protection from cisplatin- or H2O2-
induced apoptosis. (Yang et al, 2005).
We have undertaken a drug discovery programme to isolate
small-molecule inhibitors of APE1 (Madhusudan et al, 2005). In
the previously published study, we provided the first preclinical
evidence that APE1 inhibition by a small-molecule inhibitor
potentiated the cytotoxicity of a panel of base-targeting agents
thought to be repaired through BER (Madhusudan et al, 2005). To
identify drug-like leads, we recently adopted an industry-standard,
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shigh-throughput, virtual screening strategy using first-generation
inhibitors as templates and screened a chemical library of 2.6
million compounds. Several novel inhibitors of APE1 were
identified with the ability to potentiate the cytoxicity of alkylating
agents (unpublished data).
In the current study, we provide evidence that APE1 is a
prognostic marker in ovarian, gastric, and pancreatico-biliary
cancer. We demonstrate positive clinicopathological correlations
of APE1 nuclear expression in ovarian, gastric, and pancreatico-
biliary cancers, suggesting that APE1 is also a potential drug target
in these tumours.
MATERIALS AND METHODS
Study design and setting
Expression of APE1 in ovarian cancer was investigated
using a tissue microarray (TMA) of 157 ovarian cancer cases.
Tissue was obtained from patients with primary ovarian cancer
treated at Nottingham University Hospitals (NUH) between
2000 and 2007. Survival was calculated from the operation date
until 1 April 2009 when any remaining survivors were censored.
During the study period, patients were treated with either single
agent carboplatin (65 patients (41.4%)) or platinum-based
combination chemotherapy (89 patients (56.7%): 79 out of 89
patients received carboplatin and paclitaxel; 4 out of 89 received
cyclophosphamide/doxorubicin/cis-platinum (CAP); 3 out of 89
were treated in the ICON-5 trial using paclitaxel, carboplatin plus
gemcitabine, or topotecan (Bookman et al, 2009); and 3 out of 89
were treated according to the SCOTROC trial protocol by
carboplatin, docetaxel±topotecan; Kaye et al, 2009). Platinum
resistance was defined as patients who had progression during
first-line platinum chemotherapy or relapse within 6 months after
treatment.
Expression of APE1 in gastro-oesophageal cancers was investi-
gated using two TMA sets. The first set consisted of 142 gastric/
gastro-oesophageal cancer cases not exposed to neoadjuvant
chemotherapy. With recent incorporation of neoadjuvant
chemotherapy as a standard treatment option for operable
gastro-oesophageal tumours (Cunningham et al, 2006), we also
established a second TMA of 103 gastric/gastro-oesophageal cancer
cases exposed to preoperative platinum-based chemotherapy.
Tissue was obtained from patients treated at Nottingham
University Hospitals (NUH) between 2001 and 2008. Survival
was calculated from the date of diagnosis until 13 January 2009
when any remaining survivors were censored. During the study
period, patients in the neoadjuvant arm with adenocarcinomas
were treated with either neoadjuvant ECF (epirubicin (50mgm
 2),
cisplatin (60mgm
 2), and continuous infusional 5-FU
(200mgm
 2 per day)) or ECX (epirubicin (50mgm
 2), cisplatin
(60mgm
 2), and capecetabine (625mgm
 2 p.o. b.d continu-
ously)) chemotherapy up to three cycles prior to surgery. Patients
with squamous cell carcinoma were treated with CF (cisplatin
(80mgm
 2) and infusional 5-FU (1000mgm
 2 daily for 4 days);
Allum et al, 2009) chemotherapy up to two cycles prior to surgery.
Expression of APE1 in pancreatico-biliary cancer was investi-
gated using a TMA of 120 cases. All the participants were patients
who underwent pancreatic resection (for benign or malignant
pancreatic disease) between June 2001 and June 2006 at NUH
Queen’s Medical Centre Campus. Cores from 72 malignant
tumours were selected for analysis within this study, of which 34
had pancreatic adenocarcinoma (PAC), 20 had ampullary adeno-
carcinoma (AAC), and 18 had cholangiocarcinoma. Only 15
patients had received adjuvant 5-FU/folinic acid chemotherapy
in this cohort.
The conduct of this study was approved by the Ethics
Committee of Nottingham University Hospitals.
Construction of TMA
Tissue microarrays were constructed as described previously
(Kononen et al, 1998). In short, area-specialised histopathologists
identified and marked formalin-fixed, paraffin-embedded tissue
blocks containing tumour tissue on haematoxylin- and eosin-
stained slides. The marked areas in these donor paraffin blocks
were used to construct the TMA. Triplicate tissue cores with a
diameter of 0.6mm were taken from the marked areas and arrayed
into a recipient paraffin block using a tissue puncher/arrayer
(Beecher Instruments, Silver Spring, MD, USA) as previously
described (Kononen et al, 1998). Five-micrometre sections of the
tissue array block were cut and placed on Fisherbrand Colorfrost/
Plus microscope slides (Fisher Scientific, Pittsburgh, PA, USA) for
immunohistochemical staining.
Immunohistochemistry
A standard streptavidin–biotin complex method was used.
Negative controls were obtained by omitting the primary antibody
in each case. The tissue slides were deparaffinised with xylene and
then rehydrated through five decreasing concentrations of alcohol
(100, 90, 70, 50, and 30%) for 2min each. Endogenous peroxidise
activity was blocked by incubation in a 1% hydrogen peroxide/
methanol buffer. Antigen retrieval was performed by microwave
treatment of the slides in sodium citrate buffer (pH 6.0) for 10min.
The slides were rinsed in phosphate buffer solution (PBS) and
incubated with blocking serum diluted in PBS to block non-
specific staining. The slides were incubated for 1h with the
primary rabbit polyclonal anti-APE-1 antibody clone NB100-101
(Novus Biologicals Inc., Littleton, CO, USA) at a dilution of 1:500.
After washing with PBS, sections were incubated with the
secondary antibody (Vector Laboratories, Burlingame, CA, USA)
for 30min followed by the avidin–biotin complex for a further
30min. 3–30-Diaminobenzidine tetrahydochloride was used
as chromogen. All sections were counterstained with Gill’s
haematoxylin.
Evaluation of immune staining
The tumour cores were evaluated by specialist pathologists and
oncologists blinded to the clinicopathological characteristics of
patients. Whole-field inspection of the core was included in the
assessment and intensities of staining were grouped as follows:
0¼no staining; 1¼weak staining; 2¼moderate staining; and
3¼strong staining. Cytoplasmic and nuclear staining were
assessed separately for each core. Only stained malignant cells
(epithelial cancer cells in ovarian cancer, ductal and acinar
exocrine epithelial cells in pancreatico-billiary cancer) were
included in the evaluation of staining. Stained stromal cells,
inflammatory cells, and endocrine cells within islets of Langerhans
were disregarded. Nuclear and cytoplasmic score were assigned
separately for each core, and the mean of three cores was
calculated for each sample. The results shown represent the mean
score from the three cores available for each assessable patient
sample. Not all cores within the TMA were suitable for
immunohistochemistry (IHC) analyses due to small technical
problems such that some cores were missing or lacked tumours.
Statistical analysis
Statistical analysis of data was performed using SPSS version 15.0
for Windows (SPSS Inc., Chicago, IL, USA). Univariate analysis of
associations was determined using the Pearson w
2-test. Survival
rates were calculated from the time of resection until the end of
the follow-up period and Kaplan–Meier curves were plotted.
The statistical significance of differences between survival rates
was determined using the log-rank test. Survival was censored if
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sthe patient was still alive or died of other causes. P-values o0.05
were identified as statistically significant. The threshold for
significance was adjusted to o0.01 for subset analyses.
RESULTS
Patient demographics
Ovarian cancer This cohort comprised female patients with a
median age of 61 years (range 33–87, mean 60 years) (Table 1a).
Out of the 157 patients included in the study, 54 (34%) were dead
before the end of the follow-up period. Histologically, most
patients were found to have a serous cystadenocarcinoma (56%),
followed by endometrioid (21%), clear-cell carcinoma (13%),
mucinous cystadenocarcinoma (8%), or other types (2%).
Tumours displayed poor histological differentiation in 73% of
cases. The majority of tumours were classified as FIGO stage III
(45%).
Gastro-oesophageal cancer There were two groups of patients:
those who received at least one cycle of neoadjuvant chemotherapy
(neoadjuvant group) and those who underwent primary surgery
(primary group) (Table 1b). There were 103 patients in the
neoadjuvant group, with a median age of 63 years and 81% were
male. T3 tumours were the majority, constituting 62% of cases.
A total of 142 cases were in the primary group, with a median age
of 74 years: 74% were male, 53% had T3 tumours.
Pancreatico-biliary cancer Of the 72 patients with pancreatico-
bilairy tumours, 44 patients were male and 28 were female
(Table 1c). Thirty-four had PAC, 20 had AAC, and 18 had
cholangiocarcinoma. The median follow-up time was 20.4 months;
35 patients (38%) died of their cancer at the time of the
observation period, while only 12 patients (13%) were still alive
at 5 years following the operation. The median survival was 37.8
months.
APE1 expression and clinicopathological correlations
Ovarian cancer Apyrimidinic endonuclease-1 expression was
noted both in the cytoplasmic and nuclear compartments in
ovarian cancer; however, nuclear staining was more prevalent
(Table 2). Of the 135 evaluable cores, 97 had nuclear expression
(71.9%), but only 40 had cytoplasmic expression (29.6%). It was
seen more often localised to the nucleus only (45.9%) (Figure 1A)
as compared with 3.7% showing exclusively cytoplasmic staining.
There was a significant difference in the level of APE1 expression
among the different histological subtypes of ovarian cancer, with
serous and mucinous tumours displaying nuclear APE1 more
frequently than endometrioid and clear-cell carcinomas
(P¼0.006) (Table 3). Nuclear localisation of APE1 correlated with
a lower likelihood of achieving optimal debulking after initial
surgery (P¼0.009), suggesting a more aggressive phenotype. This
was also reflected on survival; APE1-positive cases had worse
Table 1a Patient demographics and pathological features for Ovarian
cancer
Characteristics Frequencies Percentages (%)
Pathology
Serous cystadenocarcinoma 88 56
Endometrioid 33 21
Clear cell carcinoma 21 13
Mucinous cystadenocarcinoma 12 8
Other 3 2
Grade
12 0 1 3
22 3 1 4
3 114 73
Residual tumour
None 88 56
Present 69 44
Stage
IC 44 28
II 21 13
III 71 45
IV 21 14
Chemotherapy
Carboplatin monotherapy 65 41
Carboplatin combination therapy 89 57
No chemotherapy 3 2
Platinum sensitivity
Sensitive 104 66
Resistant 50 32
Unknown 3 2
Relapse status
Relapsed 75 48
Relapse-free 75 48
Unknown 7 4
Survival status
Living 103 66
Dead 54 34
Table 1b Patient demographics and pathological features for Gastro-
oesophageal cancer
Characteristics
Primary
surgery
arm (n)
Percentage
(%)
Neoadjuvant
arm (n)
Percentage
(%)
Patients (n) 142 103
Median age 74 63
Sex
Male 105 73.9% 83 81%
Female 37 26% 20 19%
T stage
T1 14 9.8% 4 3.8%
T2 48 33.8% 24 23.6%
T3 75 52.8 64 62%
T4 5 3.5% 9 8.6%
TX 2 2%
N stage
N0 33 23.2% 29 28%
XN1 109 76.8% 74 72%
M stage
M0 140 98.5% 103 100%
M1 2 1.4% —
Vascular invasion
No 44 40% 57 55%
Yes 98 60% 46 45%
Perineural invasion
No 66 46% 15 15%
Yes 76 54% 88 85%
Status
Alive 54 38% 47 46%
Dead 87 62% 56 54%
APE1 expression in cancer
A Al-Attar et al
706
British Journal of Cancer (2010) 102(4), 704–709 & 2010 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
soverall survival (median survival time¼52 months) as compared
with 71 months for APE1-negative patients. This difference was
statistically significant as shown in the Kaplan–Meier graph and
log-rank test (P¼0.05) (Figure 2A). No significant correlations
were seen between APE1 and FIGO stage or with histological grade.
Platinum resistance (defined as patients who had progression
during first-line platinum chemotherapy or relapse within 6
months after treatment) was more frequently seen in APE1-
positive cases (35.8%) as compared with APE1-negative patients
(21.1%); however, this did not reach statistical significance
(P¼0.09).
Gastro-oesophageal cancer In the primary-group TMAs, 41 out of
93 tumours that were stained for APE1 showed specific nuclear
staining (44.1%) and 48 out of 93 (51.6%) were positive in the
cytoplasm compartment as well (Table 2). In the neoadjuvant-
group TMAs, 16 out of 46 tumours that were stained for APE1
showed specific nuclear staining (34.8%) (Figure 1B) and 32 out of
46 (69.6%) were positive in the cytoplasm. In the neoadjuvant
group, nuclear APE1 correlated with worse overall survival in
Table 1c Patient demographics and pathological features for Pancrea-
tico-biliary cancer
Characteristics
No of
patients
% of total
number of
recorded cases
Age (years)
o40 0
41–60 28 38.9
460 44 61.1
Sex
Male 44 61.1
Female 28 38.9
Grade
Poor 14 19.4
Well/moderate 49 68.1
Unknown 9 12.5
Lymph node status
Not involved 17 23.6
Involved 46 63.9
Unknown 9 12.5
Vascular invasion
Negative 33 45.8
Positive 37 51.4
Unknown 2 2.8
Perineural invasion
Negative 32 44.4
Positive 39 54.2
Unknown 1 1.4
T stage
0 1 1.4
1 7 9.7
2 20 27.8
3 40 55.6
4 3 4.2
Unknown 1 1.4
Outcome
Alive 26 36.1
Died of disease 30 41.7
Died of other cause 16 22.2
Site
Pancreatic 24 38.7
Ampullary 20 32.3
Cholangio 18 29
Table 2 The distribution of nuclear APE1 expression in ovarian,
pancreatico biliary, and gastric cancers (primary and neoadjuvant series)
Ovarian Pancreatic
Gastric
(primary)
Gastric
(neo-adjuvant)
Positive 97 (71.9%) 32 (44.4%) 41 (44.1%) 16 (34.8)
Negative 38 (28.1%) 40 (55.6%) 52 (55.9%) 30 (65.2%)
Total 135 (100%) 72 (100%) 93 (100%) 46 (100%)
Ovarian cancer Gastric cancer
Pancreatic cancer
Figure 1 Microphotographs of ovarian cancer (A), gastric cancer (B),
and PAC (C) showing positive nuclear APE1 expression (magnification
 200).
Table 3 Cross-tabulation of APE1 expression in ovarian cancer with
histopathological subtypes
APE1 nuclear ovarian cancer pathological subtypes – Cross-tabulation
Pathological subtypes
Serous Mucinous Endometroid
Clear
cell Other Total
APE1 nuclear
Negative
Count 14 3 12 9 0 38
% 17.9% 30.0% 42.9% 52.9% 0% 28.1%
Positive
Count 64 7 16 8 2 97
% 82.1% 70.0% 57.1% 47.1% 100.0% 71.9%
Total
Count 78 10 28 17 2 135
% 100% 100% 100% 100% 100% 100%
Abbreviation: APE1¼ apurinic/apyrimidinic endonuclease-1. A strong correlation
was found (P¼0.006).
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spatients receiving platinum-based neoadjuvant chemotherapy
(P¼0.005) (Figure 2B). Cytoplasmic APE1 correlated with tumour
differentiation (P¼0.034). No significant correlations were seen in
the primary surgery group.
Pancreatico-biliary cancer The number of cancer tissue cores
suitable for immunohistochemical analyses was 72, which
comprised PAC (n¼34) and AAC (n¼20), and cholangiocarci-
noma (n¼18) (Table 2). Overall, cytoplasmic expression of APE1
was never seen in the absence of nuclear expression in either
tumour or normal tissues. Nuclear staining only was seen in 44%
of all periampullary tumours (32 out of 72) (Figure 1C), 35% (12
out of 34) of PACs, 60% (12 out of 20) of AACs, and 44% (8 out of
18) of cholangiocarcinomas. Absence of cytoplasmic staining was
associated with vascular invasion (P¼0.05), perineural invasion
(P¼0.007), and a trend towards advanced stage (P¼0.077) and
poor differentiation (grade-3 poorly differentiated adenocarcino-
ma) (P¼0.068).
DISCUSSION
Overall prognosis of advanced melanoma, ovarian, gastro-oeso-
phageal, and pancreatico-biliary cancer remains poor. New
treatment strategies are urgently required to address this largely
unmet need. Cytotoxic agents (such as alkylating agents and
platinum compounds) and ionising radiation used in the treatment
of these tumours induce DNA damage (such as base damage and
others) in cells. Cancer cells proficient in DNA repair are able to
repair such DNA damage and continue to survive. This is a
significant cause for therapeutic resistance and impacts negatively
on patient outcomes. Pharmacological inhibition of DNA repair is
likely to enhance the cytotoxicity in cancer cells and improve
tumour response in patients. APE1 is a key multifunctional protein
essential for DNA BER, in addition to redox regulation of
transcription factors and transcriptional regulation. It is widely
accepted that nuclear expression of APE1 is involved in DNA
repair, whereas cytoplasmic expression may be involved in redox/
transcriptional regulation.
In the current study we have demonstrated the potential APE1
expression has as a negative prognostic factor in cancer patients.
Nuclear expression of APE1 was frequently seen in ovarian, gastro-
oesophageal, and pancreatico-biliary cancers. In ovarian cancer,
nuclear APE1 expression was seen commonly in serous and
mucinous tumours (P¼0.006). In addition, sub-optimal debulking
and residual tumour was seen more frequently in tumours with
nuclear expression of APE1, implying aggressive tumour biology
(P¼0.009). In fact, this was reflected in poor overall survival in
patients (P¼0.05). Interestingly, we also found evidence that
APE1 expression may predict platinum resistance in patients,
although this did not reach statistical significance (P¼0.09). The
negative prognostic impact was also seen in gastro-oesophageal
cancer where patients who received neoadjuvant platinum-based
chemotherapy and whose tumours showed APE1 nuclear expres-
sion did significantly worse as compared with non-expressors
(P¼0.005). Our study is consistent with recent preclinical
observations using melanoma cell lines where APE1 overexpres-
sion conferred protection from cisplatin (Yang et al, 2005).
Moreover, in lung cancer, blocking APE1 function potentiated
cisplatin cytotoxicity (Wang et al, 2009). These studies imply that
APE1 is involved in the repair of damage induced by platinating
agents, and current evidence suggests that the protective effect
may be contributed by the DNA repair as well as the redox-
regulatory activity of APE1. The negative prognostic significance of
APE1 has also been recently demonstrated in osteosarcoma (Wang
et al, 2004) and head and neck cancer (Koukourakis et al, 2001).
Apyrimidinic endonuclease-1 exhibits complex and heteroge-
neous staining patterns. Although the biological relevance of the
compartmentalisation of APE1 is not understood, its complexity
suggests that APE1 localisation in cells is tightly regulated. In
addition, as the nuclear expression of APE1 is involved in DNA
repair and the cytoplasmic expression may be involved in redox/
transcriptional regulation, it is speculated that the compartmenta-
listion may reflect distinct functions of APE1 in cells. The altered
subcellular localisation of APE1 in pancreatico-biliary cancers
observed in our study is distinct to observations in other tumours.
Nuclear staining only was seen in 44% of all periampullary
tumours. Combined nuclear and cytoplasmic expression was seen
in 25% of tumours. Cytoplasmic expression of APE1 was never
seen in the absence of nuclear expression. Absence of cytoplasmic
expression correlated to adverse prognostic features. This is in
contrast to tumours such as breast cancer. In normal breast tissue,
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Figure 2 Kaplan–Meier curves showing overall survival in ovarian (A) and gastric (B) cancers according to the expression of APE1. In both cases, APE1
was associated with worse survival (log-rank test P-value¼0.05 and 0.005 for ovarian and gastric cancers, respectively).
APE1 expression in cancer
A Al-Attar et al
708
British Journal of Cancer (2010) 102(4), 704–709 & 2010 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sAPE1 localisation is predominantly nuclear, whereas in breast
carcinomas, nuclear, cytoplasmic, and nuclear/cytoplasmic
stainings were observed (Kakolyris et al, 1998; Puglisi et al,
2002). Furthermore, while nuclear localisation was associated with
good prognostic features (being related to better differentiation,
low angiogenesis, and negative lymph node status), cytoplasmic
and combined nuclear/cytoplasmic localisation were associated
with poor prognostic factors, such as angiogenesis together with
node and p53 positivity (Kakolyris et al, 1998; Puglisi et al, 2002).
A dysregulation in nuclear vs cytoplasmic ratio towards increased
cytoplasmic staining was also observed in thyroid carcinomas (Tell
et al, 2000) and prostate cancer (Kelley et al, 2001).
In conclusion, we have shown prognostic implications of APE1
in ovarian, gastro-oesophageal, and pancreatico-biliary cancer.
Moreover our study suggests that APE1 is a potential drug target in
these tumours. The recent evidence of BER modulation using
PARP inhibitors that have shown promise in recent clinical trials
in ovarian and breast cancer (Lord and Ashworth, 2008), implies
that APE1 inhibitors may have similar clinical application in
patients.
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